(Circulation. 1997;96:3042-3047.)
© 1997 American Heart Association, Inc.
Articles |
Inflammatory Cytokines Impair Endothelium-Dependent Dilatation in Human Veins In Vivo
From the Centre for Clinical Pharmacology, Cruciform Project for Strategic Medical Research and Department of Medicine, University College London (UK).
Correspondence to Kiran Bhagat, BSc, PhD, MRCP, Centre for Clinical Pharmacology, University College London, London, UK. E-mail k.bhagat{at}ucl.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background Endothelial dysfunction occurs in many diseases associated with increased cardiovascular risk. We examined the effects of pro-inflammatory cytokines on endothelial function.
Methods and Results Subjects lay with one hand placed on an
angled support. The diameter of a vein was recorded by measuring
the linear displacement of a probe placed on the skin overlying the
vein when the pressure in a congesting cuff placed around the upper arm
was deflated from 40 to 0 mm Hg. A length of the vein was
isolated by two wedges. TNF-
(1 ng), IL-1ß (1 ng), or IL-6 (100
pg) were instilled for 1 hour, either individually or together. At the
end of the hour, the wedges were removed and the vein reconnected with
the circulation. Dose-response curves (bradykinin: 2, 4, and 8
pmol/min; arachidonic acid: 0.2, 2, and 20 nmol/min;
and glyceryl trinitrate 1, 2, and 4 pmol/min) were constructed before
and 1, 6, 24, and 48 hours after instillation. In another study,
hydrocortisone (100 mg) was given 2 hours before the study. In a
different study, subjects were given oral aspirin (75 mg or 1 g) 2
hours before the study. TNF- and IL-1ß alone but not IL-6
attenuated the dilatation to bradykinin and arachidonic
acid; the response was greatest at 1 hour with recovery occurring by 6
hours. Combination of IL-1ß and TNF- prolonged the
endothelial dysfunction, resulting in recovery at 24
hours. Hydrocortisone and high-dose aspirin prevented
endothelial dysfunction.
Conclusions The results demonstrate that pro-inflammatory cytokines induce transient and reversible endothelial dysfunction and indicate that cyclooxygenase activity may contribute to the genesis of the effect. If other vessels behave similarly, this may provide further insight into the mechanisms precipitating acute cardiovascular events after inflammatory disorders.
Key Words: endothelium • vasodilation • bradykinin • interleukins • prostaglandins
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Normal endothelial function maintains cardiovascular homeostasis.1 The endothelium produces anti-platelet, anti-clotting, and fibrinolytic factors1 and regulates vascular tone through the production of constrictor and dilator mediators, including endothelin, nitric oxide, and prostacyclin.1 2 In experimental models endothelial dysfunction promotes thrombosis, vasospasm, and vessel occlusion and has been implicated in the pathogenesis of acute myocardial infarction, stroke, and other cardiovascular disorders.3
Consistent with the link between endothelial dysfunction and cardiovascular disease, smoking,4 hypertension,5 diabetes,6 and hyperlipidemia7 have all been associated with impaired endothelium-dependent dilatation in studies in animals and humans. However, these are chronic and often relatively stable risk factors for cardiovascular disease; recent epidemiological studies have recognized another more acute risk factor for unstable angina, myocardial infarction, and stroke: that of infection.11 A number of reports have indicated that a preceding febrile illness or a bacteremic episode is associated with a markedly increased risk of an acute cardiovascular event for several weeks after the illness.12 13 In a previous study in healthy volunteers, we demonstrated that a brief exposure to bacterial endotoxin impairs endothelium-dependent relaxation for many days14 and suggested that transient "stunning" of endothelial function might provide a mechanism linking infection to increased risk of infarction.
Cytokines mediate many of the biological effects of
endotoxin,15 and local concentrations of certain
pro-inflammatory cytokines are significantly elevated in
patients with unstable angina and myocardial
infarction.16 17 18 Indeed, it has been suggested that an
inflammatory response associated with cytokine production might trigger
the transition from stable to unstable
atheroma.8 In the present study we report
on the effects of TNF-, IL-1ß, and IL-6 on
endothelial function in healthy volunteers and assess
the effects of anti-inflammatory drugs on the responses seen.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Studies were approved by the local ethics committee and were performed on male and female subjects aged 19 to 40 years. Subjects were included who stated that they were healthy and on no medication, and who gave their informed, written consent. Subjects lay supine in a temperature-controlled laboratory (28°C to 30°C). A congesting cuff was placed around the upper arm and inflated to 40 mm Hg. Drugs or physiological saline were infused through a 23-gauge needle placed in a dorsal hand vein. The diameter of the vein was measured 10 to 15 mm downstream from the tip of the infusion needle by recording the linear displacement of a lightweight probe placed on the skin overlying the summit of the vessel when the pressure in the congesting cuff was lowered from 40 to 0 mm Hg.19 In all studies, saline was infused for at least 15 minutes until a stable baseline vein diameter was recorded. Provided that subjects are comfortably warm and relaxed, dorsal hand veins have no intrinsic tone,20 and basal vein size remains constant over days and weeks. To observe dilator responses it is necessary to preconstrict the vessel, and we did this with norepinephrine. Dose-response curves to endothelium-dependent and independent dilators were constructed before and after exposure of the vessel to cytokines. The subsequent increase in vein size was expressed as a percentage reversal from the preconstricted state.
 |
Instillation of Cytokines
To instill cytokines, a length of the vein under study
was isolated from the circulation by means of two wedges placed 2 to 3
cm apart on the skin overlying the vessel as described
previously.19 TNF- (1 ng in 1 mL saline), IL-1ß (1 ng
in 1 mL saline), and IL-6 (100 pg in 1 mL saline) were instilled for 1
hour, either individually or together. At the end of the period of
instillation, the wedges were removed and the vein was reconnected with
the circulation for assessment of reactivity. This method of
instillation produces local changes in the study vein but adjacent
vessels remain unaffected.19 The volume of blood in the
isolated vein is in the order of 1 to 2 mL, and the calculated
concentration of cytokine was in the order of 300 to 1000
pg/mL (TNF- and IL-1ß) and 30 to 100 pg/mL
(IL-6).
Dilator Dose-Response Curves
Vessels were preconstricted to approximately 50% of resting
diameter by a continuous infusion of norepinephrine (5 to
640 pmol/min). To construct cumulative dose-response curves,
bradykinin (2, 4, and 8 pmol/min, each dose for 5 minutes),
arachidonic acid (0.2, 2, and 20 nmol/min, each
dose for 5 minutes), or GTN (1, 2, and 4 pmol/min, each dose for
5 minutes) was co-infused with the norepinephrine and
relaxation recorded. In these vessels, bradykinin activates
nitric oxide synthase in the
endothelium,21 22
arachidonic acid stimulates prostanoid
production,19 and GTN is a nitric oxide donor that
acts directly on smooth muscle. In all studies, a 10 to 15-minute
washout period (infusion of norepinephrine alone) separated
the dose response to different agonists.
Effects of Cytokines
In 40 subjects dilator dose-response curves were constructed
before and at 1, 6, 24, and 48 hours after instillation of either
TNF- alone, IL-1ß alone, IL-6 alone, TNF- and IL-1ß together,
or TNF-, IL-1ß, and IL-6 together. To construct a time course,
each individual was studied on several occasions. To ensure that the
same site of the study vein was assessed at different time points, an
indelible mark was placed at the site of the needle insertion and the
point at which measurements were taken.
Effects of Anti-inflammatory Drugs on the Response to
Cytokines
Hydrocortisone
Subjects were given oral hydrocortisone (100 mg) 2 hours before
the study, and dilator dose-response curves were constructed before and
1 hour after instillation of TNF- alone (n=5), IL-1ß alone (n=5),
or a combination of TNF-, IL-1ß, and IL-6 (n=5).
Aspirin
Subjects were given oral aspirin (75 mg or 1 g) 2 hours
before the study and dilator dose-response curves were constructed
before and 1 hour after instillation of TNF- alone (n=5; highest
dose of aspirin only) or a combination of TNF-, IL-1ß, and IL-6
(n=5; each subject studied twice, once with high-dose and once with
low-dose aspirin).
Drugs
IL-1ß (10 µg), TNF- (10 µg), and IL-6 (10 µg) were
obtained from Bachem, bradykinin from Clinalpha AG, hydrocortisone (20
mg/tablet) from MSD, norepinephrine (2
mg/vial) from Sanofi Winthrop, ascorbic acid (100 mg/mL)
from Evans Medical Ltd, and heparin (100 U/mL) from CP Pharmaceuticals
Ltd. Sodium arachidonate (5 mg/vial) stored under
nitrogen was obtained from Sigma. Vials were stored at -20°C and a
single vial was used for each study. Sodium arachidonate (5
mg) was dissolved in 154 µL absolute alcohol to produce a stock
solution of 1 mmol/L. Subsequent dilution was in saline,
and the final concentration of alcohol in the infusate was 0.0001%.
Arachidonic acid always was used within 1 hour of
preparation. Ascorbic acid was added to norepinephrine
stock solutions to prevent auto-oxidation. Heparin (100 U/mL) was added
to the cytokine solution before administration to prevent thrombus
formation. All solutions of cytokines and bradykinin were
filtered through a 0.2-µm bacterial filter (Acrodisc PF, Gelman
Science).
Calculations and Statistics
Changes in vein size were measured in arbitrary units and
converted to millimeters after calibration of the transducer at the end
of each experiment. The response of the resting vein to drugs is
expressed as a reduction in diameter from that measured during infusion
of saline alone. The response of the
norepinephrine-preconstricted vein to drugs is expressed as
percentage reversal of the induced constriction as described
above.14 Results are compared using Student's
t test for paired data or ANOVA of the means as appropriate;
a value of P<.05 is considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Neither TNF-
alone nor IL-6 alone affected the constrictor
response to norepinephrine. However, IL-1ß alone and
combinations of IL-1ß with the other cytokines decreased the
constrictor responses; to maintain the same degree of preconstriction,
the norepinephrine dose was increased as necessary
(Table
).
|
Effects of Cytokines on Dilator Response
TNF- and IL-1ß attenuated the dilatation to bradykinin and
arachidonic acid (Figs 1 and 2). IL-6 was without effect. The
duration of the effect of TNF- alone or IL-1ß alone was
short-lived, and the dilatation to bradykinin and
arachidonic acid returned to normal by 6 hours.
Combining TNF-, IL-1ß, and IL-6 did not increase the magnitude of
the effect on endothelium-dependent dilatation but
increased the duration (Fig 3). When all
three cytokines were instilled together for 1 hour, the
impairment of endothelium-dependent dilatation
persisted for at least 24 hours (Fig 3). In contrast to the effects of
cytokines on endothelium-dependent dilatation,
the response to GTN was unaltered by instillation of cytokines
(Fig 4).
|
)
and 1 (
) and 6 (
) hours after TNF-
|
|
|
Effects of Anti-inflammatory Drugs on the Response to
Cytokines
Hydrocortisone
Prior administration of oral hydrocortisone prevented the effects
of cytokines on dilatation to bradykinin and
arachidonic acid (Fig 5).
For example, in the hydrocortisone pretreatment group the dilatation to
bradykinin (2, 4, and 8 pmol/min) was 19±5%, 43±4%, and
81±9% before, and 21±5%, 64±11%, and 89±7% 1 hour after
instillation of TNF , IL-1ß, and IL-6. Similarly, the dilatation
to arachidonic acid before instillation of the
cytokines was 19±6%, 42±10%, and 81±9%, and 1 hour after
instillation of TNF-, IL-1ß, and IL-6 was 81±4%, 50±6%, and
94±4%.
|
) were constructed before (open
symbols) and 1 hour after (closed symbols) instillation. Doses of
arachidonic acid: point A=0.2 nmol/min; B=2 nmol/min;
and C=20 nmol/min. Doses of bradykinin: point A=2 pmol/min; B=4
pmol/min; and C=8 pmol/min.
Aspirin
Prior administration of high-dose aspirin (1 g) significantly
attenuated (P<.05) the inhibitory effects of
either TNF alone or the combination of TNF-, IL-1ß, and IL-6
(Fig 6A and 6B). However, pretreatment
with low-dose aspirin was without effect (Fig 6C).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The results of this study in healthy volunteers demonstrate that a brief (1 hour) exposure to certain pro-inflammatory cytokines results in prolonged but reversible endothelial dysfunction that we previously have termed endothelial stunning. Doses of cytokines sufficient to produce a local concentration similar to those that occur during infective and noninfective inflammatory states,16 17 18 23 24 25 26 caused prolonged and profound endothelial stunning and this effect was prevented by aspirin, suggesting that cyclooxygenase activity contributed to the genesis of the dysfunction. This is the first demonstration that cytokines impair endothelium-dependent dilatation in humans and suggests a novel cardioprotective effect of aspirin.
In our earlier study we demonstrated that a brief exposure to endotoxin
impairs endothelium-dependent relaxation for several
days.14 This effect also was seen when human saphenous
vein was incubated with endotoxin in vitro and was not due to
structural damage to the endothelial
layer.14 Similarly, it has been reported that acute
exposure to endotoxin impairs the production of nitric oxide in
response to bradykinin in bovine endothelial cells in
culture.27 In the present study, we have explored the
effects of three cytokines that have been implicated in
mediating inflammatory response and that are found in elevated local
concentrations in the plasma of patients with acute myocardial
infarction or unstable angina.16 17 18 25 26 In our vein
model,19 IL-1ß and TNF- impaired the relaxant
responses to bradykinin (a mediator that acts through stimulation of
nitric oxide production in these vessels21 22 ) and
to arachidonic acid (the precursor of prostanoid
synthesis28 ). The effect was specific for
endothelium-dependent dilators, and the response to the
nitric oxide donor GTN was unaltered. IL-6 had no effect on its own,
but the combination of all three cytokines produced the most
long-lasting impairment of endothelium-dependent
relaxation, with recovery occurring only by 48 hours. The manouver of
isolating and wedging the vein for 1 hour in the absence of
cytokines does not by itself affect responses to
norepinephrine, bradykinin, or arachidonic
acid.19 29
We took care to ensure that the degree of preconstriction was identical
for each study (Table
). IL-1ß induced hyporesponsiveness to
norepinephrine have described previously,29
and we needed to use more norepinephrine to produce the
same degree of constriction after instillation of this cytokine.
However, it is unlikely that the impaired relaxation we observed was
due to differences in the amount of norepinephrine required
to preconstrict the vessels for the different parts of the study, since
TNF- alone did not alter the constrictor response to
norepinephrine but was the most effective cytokine
at producing selective impairment of
endothelium-dependent relaxation. Furthermore,
high-dose aspirin abolished the endothelial stunning
induced by the combination of TNF-, IL-1ß, and IL-6 without
affecting the hyporesponsiveness to norepinephrine. The
transient hyporesponsiveness to norepinephrine produced by
IL-1ß is due to induction of basal nitric oxide generation and can be
reversed by nitric oxide synthase
inhibitors.29 30
Prior administration of hydrocortisone prevented the inhibitory actions of the cytokines on endothelial dilator function, suggesting that expression of inflammatory enzymes and generation of local inflammatory mediators were responsible for the effects seen. An anti-inflammatory dose (1 g) of aspirin significantly reduced the effects of cytokines on endothelial function, whereas a low cardioprotective dose (75 mg) of aspirin had no effect. We have previously shown that this anti-inflammatory dose of aspirin (1 g) abolishes vascular prostanoid synthesis in the hand veins, whereas a low dose of 75 mg of aspirin abolishes arachidonic acid-induced platelet aggregation without affecting arachidonic acid-induced venodilatation.28 Although it is possible that hydrocortisone produced some mineralocorticoid effects and that aspirin induced some degree of acute sodium reabsorption, the most likely explanation is that these agents exerted anti-inflammatory effects on the vessel wall and that the endothelial stunning induced by cytokines depends on local prostanoid synthesis. One possibility is that inducible cyclooxygenase (COX)-II was expressed in response to cytokines, and that the activity of this enzyme contributes to the endothelial stunning. It seems unlikely that COX-I activity in the endothelium was responsible, since the usual dilatation to arachidonic acid28 was not reduced after cytokine treatment.
TNF- appears to be a key cytokine inducing
endothelial dysfunction. Administration of TNF-
depresses endothelium-dependent relaxation in
vivo,31 and in vitro TNF- reduces the half-life of mRNA
coding for nitric oxide synthase.32 In addition, in
patients with heart failure, significantly elevated levels of TNF-
have been documented33 and, in experimental heart failure,
reduced gene expression of endothelial nitric oxide
synthase and COX-I activity has been reported.34 It is not
known whether COX-II activity contributes to these effects of TNF-;
however, generation of free radicals as a byproduct of COX
activity35 might affect endothelial
function. Studies in animals have shown that the
endothelial dilator dysfunction that occurs during
endotoxemia is significantly restored in the presence of free radical
scavengers.36 Although it is possible that induction of
nitric oxide generation contributed to the effects produced by IL-1ß,
it is unlikely that increased synthesis of nitric oxide due to
expression of the inducible isoform of nitric oxide synthase made a
major contribution to the effects we observed, since TNF- alone does
not induce nitric oxide synthesis in this model.29 Further
studies will be required to explore these mechanisms and to understand
why such a brief (1 hour) exposure to cytokines causes such
prolonged (lasting at least 24 hours) stunning of normal
endothelial dilator activity.
The model we have developed allows the safe study of the effects of cytokines on a human blood vessel in situ. The cytokines were instilled in doses sufficient to produce a local concentration similar to those found in patients with certain infections,37 acute myocardial infarction, and unstable angina.16 17 18 25 26 The effects are generated locally within the blood vessel, and our previous studies have indicated that even an adjacent vessel on the same hand is unaffected by agents instilled into the isolated segment. Of course, we do not know whether the observations made in the superficial hand vein are relevant to what might happen in the coronary or carotid artery or other clinically important vessels, and it would be important to extend these studies to determine whether arterial endothelium is also affected by exposure to cytokines. However, the pharmacology and physiology of the hand veins are similar to those of the saphenous vein,22 38 39 40 a vessel widely used for bypass grafting,41 and we studied the vessels in situ in the usual physiological environment.
What are the potential clinical implications of our study? The
incidence of acute myocardial events or stroke appears to rise
significantly after a febrile or bacteremic
illness.11 12 13 We have reported previously that bacterial
endotoxin impairs endothelial function for several
days.19 We now show that certain cytokines that
might be generated in a much wider range of infectious or inflammatory
conditions, and which have been implicated in the pathogenesis of acute
cardiovascular events,16 17 18 25 26 also
impair endothelium-dependent dilatation in healthy
volunteers in vivo. TNF- appears to be the critical cytokine
in this process. The impairment is not only confined to the
L-arginine-nitric oxide pathway but also affects dilator
prostanoid production. If other human vessels are affected by
these inflammatory cytokines in the same way as the hand veins
are, our results demonstrate a mechanism by which an acute inflammatory
response (for example, due to infection or surgery) might be linked to
transiently increased risk of acute cardiovascular
events including deep vein thrombosis. It remains to be determined
whether the protective effects of aspirin we observed contribute to the
efficacy of this drug in unstable angina or acute myocardial
infarction.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
Kiran Bhagat is supported by the British Heart Foundation.
Received April 4, 1997; revision received May 22, 1997; accepted May 28, 1997.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med.. 1990;323:27-36.[Medline] [Order article via Infotrieve]
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature.. 1980;288:373-376.[Medline] [Order article via Infotrieve]
3.
Luscher TF. The endothelium and
cardiovascular disease—a complex relation.
N Engl J Med.. 1994;330:1081-1083.
4. Zhu BQ, Parmley WW. Hemodynamic and vascular effects of active and passive smoking. Am Heart J.. 1995;130:1270-1275.[Medline] [Order article via Infotrieve]
5. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens.. 1992;10:1025-1031.[Medline] [Order article via Infotrieve]
6. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest.. 1992;90:2548-2554.
7. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet.. 1992;340:1430-1432.[Medline] [Order article via Infotrieve]
8.
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL,
Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of
C-reactive protein and serum amyloid a protein in severe unstable
angina. N Engl J Med.. 1994;331:417-424.
9. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J. 1993;14(Suppl K):12-16.
10. Syrjanen J. Infection as a risk factor for cerebral infarction. Eur Heart J. 1993;14(Suppl K):17-19.
11. Syrjanen J, Valtonen VV, Iivanainen M, Kaste M, Huttunen JK. Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J (Clin Res Ed).. 1988;296:1156-1160.
12. Pesonen E, Siitonen O. Acute myocardial infarction precipitated by infectious disease. Am Heart J.. 1981;101:512-513.[Medline] [Order article via Infotrieve]
13. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol.. 1984;53:481-482.[Medline] [Order article via Infotrieve]
14. Bhagat K, Moss R, Collier J, Vallance P. Endothelial stunning following a brief exposure to endotoxin—a mechanism to link infection and infarction. Cardiovasc Res.. 1996;32:822-829.[Medline] [Order article via Infotrieve]
15. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology.. 1993;187:403-416.[Medline] [Order article via Infotrieve]
16. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, Gok H, Ozdemir M. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology.. 1993;44:332-337.
17.
Guillen I, Blanes M, Gomez Lechon MJ, Castell JV.
Cytokine signaling during myocardial infarction:
sequential appearance of IL-1 beta and IL-6. Am J
Physiol.. 1995;269:R229-R235.
18. Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, Morita E. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J.. 1993;126:1299-1304.[Medline] [Order article via Infotrieve]
19.
Bhagat K, Collier J, Vallance P. Local venous
responses to endotoxin in humans. Circulation.. 1996;94:490-497.
20. Collier JG. Veins on the back of the hand. In: Harcus, Adamson, eds. Arteries and Veins. London, England: Churchill Livingstone; 1975:136-142.
21. Vallance P, Patton S, Bhagat K, MacAllister R, Radomski M, Moncada S, Malinski T. Direct measurement of nitric-oxide in human-beings. Lancet.. 1995;346:153-154.[Medline] [Order article via Infotrieve]
22. Vallance P, Collier J, Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res.. 1989;23:1053-1057.[Medline] [Order article via Infotrieve]
23. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore D, Wolff S, Burke J, Dinarello C. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis.. 1990;161:79-84.[Medline] [Order article via Infotrieve]
24. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet.. 1988;166:147-153.[Medline] [Order article via Infotrieve]
25.
Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H,
Jochum M, Schomig A. Cardiac release of cytokines and
inflammatory responses in acute myocardial infarction.
Circulation.. 1995;92:748-755.
26. Tashiro H, Shimokawa H, Yamamoto K, Nagano M, Momohara M, Muramatu K, Takeshita A. Monocyte-related cytokines in acute myocardial infarction. Am Heart J.. 1995;130:446-452.[Medline] [Order article via Infotrieve]
27. Myers PR, Parker JL, Tanner MA, Adams HR. Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production in vascular endothelium. Shock.. 1994;1:73-78.[Medline] [Order article via Infotrieve]
28.
Bhagat K, Collier J, Valiance P. Vasodilatation
to arachidonic-acid in humans—an insight into
endogenous prostanoids and effects of aspirin.
Circulation.. 1995;92:2113-2118.
29. Bhagat K, Collier J, Valiance P. Smooth muscle and endothelial dysfunction following a brief exposure to endotoxin or cytokines. Clin Sci.. 1996;91:15p. Abstract.
30. Bhagat K, Vallance P. Induction of nitric-oxide synthase in healthy-volunteers. Circulation.. 1996;94:856. Abstract.
31.
Wang P, Ba ZF, Chaudry IH. Administration of
tumor necrosis factor-alpha in vivo depresses
endothelium-dependent relaxation. Am
J Physiol.. 1994;266:H2535-H2541.
32. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res.. 1993;73:205-209.[Abstract]
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med.. 1990;323:236-241.[Abstract]
34.
Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G,
Xu XB, Kobari Y, Pritchard K Jr, Sessa WC, Hintze TH. Reduced
gene expression of vascular endothelial NO synthase and
cyclooxygenase-1 in heart failure.
Circ Res.. 1996;78:58-64.
35. Darely-Usmar V, Halliwell B. Reactive nitrogen species, reactive oxygen species, transition metal irons and the vascular system. Pharm Res.. 1996;13:649-662.[Medline] [Order article via Infotrieve]
36. Siegfried MR, Ma XL, Lefer AM. Splanchnic vascular endothelial dysfunction in rat endotoxemia: role of superoxide radicals. Eur J Pharmacol.. 1992;212:171-176.[Medline] [Order article via Infotrieve]
37.
Casey LC, Balk RA, Bone RC. Plasma
cytokine and endotoxin levels correlate with survival in
patients with the sepsis syndrome. Ann Intern Med.. 1993;119:771-778.
38. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol.. 1981;11:237-243.[Medline] [Order article via Infotrieve]
39.
MacAllister RJ, Calver AL, Riezebos J, Collier J,
Vallance P. Relative potency and arteriovenous selectivity of
nitrovasodilators on human blood vessels: an insight into the targeting
of nitric oxide delivery. J Pharmacol Exp Ther.. 1995;273:154-160.
40. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins—1. Br J Clin Pharmacol.. 1994;38:181-196.[Medline] [Order article via Infotrieve]
41. Luscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, Yang ZH, Turina M, Gradel E, Weber E, Buhler FR. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med.. 1988;319:462-467.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  D.-E. Lee, S. Kehlenbrink, H. Lee, M. Hawkins, and J. S. Yudkin Getting the message across: mechanisms of physiological cross talk by adipose tissue Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1210 - E1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Cypiene, M Kovaite, A Venalis, J Dadoniene, R Rugiene, Z Petrulioniene, L Ryliskyte, and A Laucevicius Arterial wall dysfunction in systemic lupus erythematosus Lupus, May 1, 2009; 18(6): 522 - 529. [Abstract] [PDF]
|
|
|
|
 |
|
 P. K.-T. Li, B. C.-H. Kwan, C. C. Szeto, and G. T.-C. Ko Metabolic syndrome in peritoneal dialysis patients NDT Plus, August 1, 2008; 1(4): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Wassink, Y. Van Der Graaf, S. S Soedamah-Muthu, W. Spiering, and F. L. Visseren Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 114 - 122. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Higashi, C. Goto, D. Jitsuiki, T. Umemura, K. Nishioka, T. Hidaka, H. Takemoto, S. Nakamura, J. Soga, K. Chayama, et al. Periodontal Infection Is Associated With Endothelial Dysfunction in Healthy Subjects and Hypertensive Patients Hypertension, February 1, 2008; 51(2): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vlachopoulos, K. Aznaouridis, A. Dagre, C. Vasiliadou, C. Masoura, E. Stefanadi, J. Skoumas, C. Pitsavos, and C. Stefanadis Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects Eur. Heart J., September 1, 2007; 28(17): 2102 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C.H. Kwan, M. A. Murtaugh, and S. Beddhu Associations of Body Size with Metabolic Syndrome and Mortality in Moderate Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M Cubbon, A. Rajwani, and S. B Wheatcroft The impact of insulin resistance on endothelial function, progenitor cells and repair Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 103 - 111. [Abstract] [PDF]
|
|
|
|
 |
|
 A. G. Zenovich and D. A. Taylor CELL THERAPY IN KIDNEY DISEASE: CAUTIOUS OPTIMISM... BUT OPTIMISM NONETHELESS Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S94 - S103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Shen, L. Zhang, Y. Gan, X. Wang, J. Wang, S. A. LeMaire, J. S. Coselli, and X. L. Wang Up-regulation of PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome Ten) Mediates p38 MAPK Stress Signal-induced Inhibition of Insulin Signaling: A CROSS-TALK BETWEEN STRESS SIGNALING AND INSULIN SIGNALING IN RESISTIN-TREATED HUMAN ENDOTHELIAL CELLS J. Biol. Chem., March 24, 2006; 281(12): 7727 - 7736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gulbins and P. L. Li Physiological and pathophysiological aspects of ceramide Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R11 - R26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Vlachopoulos, I. Dima, K. Aznaouridis, C. Vasiliadou, N. Ioakeimidis, C. Aggeli, M. Toutouza, and C. Stefanadis Acute Systemic Inflammation Increases Arterial Stiffness and Decreases Wave Reflections in Healthy Individuals Circulation, October 4, 2005; 112(14): 2193 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bruunsgaard Physical activity and modulation of systemic low-level inflammation J. Leukoc. Biol., October 1, 2005; 78(4): 819 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mittermayer, J. Pleiner, G. Schaller, S. Zorn, K. Namiranian, S. Kapiotis, G. Bartel, M. Wolfrum, M. Brugel, J. Thiery, et al. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1752 - H1757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Buckley, G. E. Rainger, G. B. Nash, and K. Raza Endothelial cells, fibroblasts and vasculitis Rheumatology, July 1, 2005; 44(7): 860 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. B. Tripathi, B. K. Singh, R. S. Pandey, and M. Kumar BHUx: A Patent Polyherbal Formulation to Prevent Atherosclerosis Evid. Based Complement. Altern. Med., June 1, 2005; 2(2): 217 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Berg and P. E. Scherer Adipose Tissue, Inflammation, and Cardiovascular Disease Circ. Res., May 13, 2005; 96(9): 939 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. W. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma Adipokines: molecular links between obesity and atheroslcerosis Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2031 - H2041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mozaffarian, E. B Rimm, I. B King, R. L Lawler, G. B McDonald, and W. C Levy trans Fatty acids and systemic inflammation in heart failure Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1521 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M A Shehab, R J MacFadyen, M McLaren, R Tavendale, J J F Belch, and A D Struthers Sudden unexpected death in heart failure may be preceded by short term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study Heart, November 1, 2004; 90(11): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fichtlscherer, S. Breuer, and A. M. Zeiher Prognostic Value of Systemic Endothelial Dysfunction in Patients With Acute Coronary Syndromes: Further Evidence for the Existence of the "Vulnerable" Patient Circulation, October 5, 2004; 110(14): 1926 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Clapp, A. D. Hingorani, R. K. Kharbanda, V. Mohamed-Ali, J. W. Stephens, P. Vallance, and R. J. MacAllister Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress Cardiovasc Res, October 1, 2004; 64(1): 172 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Prasad and A. A. Quyyumi Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome Circulation, September 14, 2004; 110(11): 1507 - 1512. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Quinones, M. Hernandez-Pampaloni, H. Schelbert, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, Y. Chon, H. Yang, S. B. Nicholas, et al. Coronary Vasomotor Abnormalities in Insulin-Resistant Individuals Ann Intern Med, May 4, 2004; 140(9): 700 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mozaffarian, T. Pischon, S. E Hankinson, N. Rifai, K. Joshipura, W. C Willett, and E. B Rimm Dietary intake of trans fatty acids and systemic inflammation in women Am. J. Clinical Nutrition, April 1, 2004; 79(4): 606 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L S Rallidis, M G Zolindaki, P C Pentzeridis, K P Poulopoulos, A H Velissaridou, and T S Apostolou Raised concentrations of macrophage colony stimulating factor in severe unstable angina beyond the acute phase are strongly predictive of long term outcome Heart, January 1, 2004; 90(1): 25 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Esposito, C. Di Palo, R. Marfella, and D. Giugliano The Effect of Weight Loss on Endothelial Functions in Obesity: Response to Sciacqua et al. Diabetes Care, October 1, 2003; 26(10): 2968 - 2969. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. R. Gill, M. J. Caslake, C. McAllister, F. Tsofliou, W. R. Ferrell, C. J. Packard, and D. Malkova Effects of Short-Term Detraining on Postprandial Metabolism, Endothelial Function, and Inflammation in Endurance-Trained Men: Dissociation between Changes in Triglyceride Metabolism and Endothelial Function J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4328 - 4335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Muzaffar, J Y Jeremy, G D Angelini, K Stuart-Smith, and N Shukla Role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries Thorax, July 1, 2003; 58(7): 598 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Yki-Jarvinen, R Bergholm, and M Leirisalo-Repo Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis Ann Rheum Dis, July 1, 2003; 62(7): 630 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chia, M. Qadan, R. Newton, C. A. Ludlam, K. A.A. Fox, and D. E. Newby Intra-Arterial Tumor Necrosis Factor-{alpha} Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 695 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bruunsgaard, H. E. Poulsen, B. K. Pedersen, K. Nyyssonen, J. Kaikkonen, and J. T. Salonen Long-Term Combined Supplementations with {alpha}-Tocopherol and Vitamin C Have No Detectable Anti-Inflammatory Effects in Healthy Men J. Nutr., April 1, 2003; 133(4): 1170 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Filer, J M Gardner-Medwin, J Thambyrajah, K Raza, D M Carruthers, R J Stevens, L Liu, S E Lowe, J N Townend, and P A Bacon Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa Ann Rheum Dis, February 1, 2003; 62(2): 162 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. X. Zhang, F.-X. Yi, A.-P. Zou, and P.-L. Li Role of ceramide in TNF-alpha -induced impairment of endothelium-dependent vasorelaxation in coronary arteries Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1785 - H1794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bergholm, M. Leirisalo-Repo, S. Vehkavaara, S. Makimattila, M.-R. Taskinen, and H. Yki-Jarvinen Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1637 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Venugopal, S. Devaraj, I. Yuhanna, P. Shaul, and I. Jialal Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells Circulation, September 17, 2002; 106(12): 1439 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pleiner, F. Mittermayer, G. Schaller, R. J. MacAllister, and M. Wolzt High Doses of Vitamin C Reverse Escherichia coli Endotoxin-Induced Hyporeactivity to Acetylcholine in the Human Forearm Circulation, September 17, 2002; 106(12): 1460 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Esposito, A. Pontillo, M. Ciotola, C. Di Palo, E. Grella, G. Nicoletti, and D. Giugliano Weight Loss Reduces Interleukin-18 Levels in Obese Women J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3864 - 3866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Kharbanda, B. Walton, M. Allen, N. Klein, A. D. Hingorani, R. J. MacAllister, and P. Vallance Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin Circulation, June 4, 2002; 105(22): 2600 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stollberger and J. Finsterer Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ford Leukocyte Count, Erythrocyte Sedimentation Rate, and Diabetes Incidence in a National Sample of US Adults Am. J. Epidemiol., January 1, 2002; 155(1): 57 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel Endothelial dysfunction and inflammation--is there a link? Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1968 - 1971. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Behr, S. S. Nerurkar, A. H. Nelson, R. W. Coatney, T. N. Woods, A. Sulpizio, S. Chandra, D. P. Brooks, S. Kumar, J. C. Lee, et al. Hypertensive End-Organ Damage and Premature Mortality Are p38 Mitogen-Activated Protein Kinase-Dependent in a Rat Model of Cardiac Hypertrophy and Dysfunction Circulation, September 11, 2001; 104(11): 1292 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus JAMA, July 18, 2001; 286(3): 327 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Chambers, D. O. Haskard, and J. S. Kooner Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome J. Am. Coll. Cardiol., February 1, 2001; 37(2): 517 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. PASSAUER, E. BÜSSEMAKER, U. RANGE, M. PLUG, and P. GROSS Evidence In Vivo Showing Increase of Baseline Nitric Oxide Generation and Impairment of Endothelium-Dependent Vasodilation in Normotensive Patients on Chronic Hemodialysis J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1726 - 1734. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Hingorani, J. Cross, R. K. Kharbanda, M. J. Mullen, K. Bhagat, M. Taylor, A. E. Donald, M. Palacios, G. E. Griffin, J. E. Deanfield, et al. Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans Circulation, August 29, 2000; 102(9): 994 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ikonomidis, F. Andreotti, E. Economou, C. Stefanadis, P. Toutouzas, and P. Nihoyannopoulos Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin Circulation, August 24, 1999; 100(8): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bhagat, A. D Hingoranil, M. Palacios, I. G Charles, and P. Vallance Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS Cardiovasc Res, March 1, 1999; 41(3): 754 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bhagat Endothelial function and myocardial infarction Cardiovasc Res, August 1, 1998; 39(2): 312 - 317. [Full Text] [PDF]
|
|
|
|
|
|
D. X. Zhang, A.-P. Zou, and P.-L. Li Ceramide Reduces Endothelium-Dependent Vasodilation by Increasing Superoxide Production in Small Bovine Coronary Arteries Circ. Res., April 27, 2001; 88(8): 824 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ziccardi, F. Nappo, G. Giugliano, K. Esposito, R. Marfella, M. Cioffi, F. D'Andrea, A. M. Molinari, and D. Giugliano Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year Circulation, February 19, 2002; 105(7): 804 - 809. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||